Yuankai Shi
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China (NCT04857164) | Yuankai Shi | 2021-04-30 |
Track Yuankai Shi automatically
Every clearance here is in the API, with alerts when new ones post.